CJC-1295 with DAC (Research Peptide): Mechanism, Half-Life, and Scientific Overview

CJC-1295 with DAC is a synthetic growth hormone-releasing hormone (GHRH) analog studied in endocrine and metabolic research. It is designed to stimulate the pituitary gland to increase endogenous growth hormone (GH) and downstream IGF-1 signaling, with a significantly extended duration of action compared to natural GHRH.

The defining feature of this compound is the Drug Affinity Complex (DAC) modification, which allows prolonged binding to serum albumin and results in sustained hormonal activity in research models.

---

What Is CJC-1295 with DAC?

CJC-1295 is a modified version of the first 29 amino acids of GHRH, engineered to resist enzymatic breakdown and extend biological activity.

The DAC version includes a chemical group that binds to albumin in the bloodstream, dramatically increasing half-life and exposure time.

Key research characteristics include:

• Synthetic GHRH analog
• Albumin-binding DAC modification
• Long-acting endocrine signaling compound
• Used in GH axis research models

---

How CJC-1295 with DAC Works

CJC-1295 with DAC acts on the growth hormone-releasing hormone receptor (GHRH-R) in the anterior pituitary gland.

Once bound, it activates intracellular signaling pathways that stimulate growth hormone release:

• cAMP/PKA signaling cascade
• CREB-mediated gene transcription
• Increased GH secretion
• Elevated IGF-1 production in liver tissue models

These effects are studied in relation to metabolic regulation and hormonal rhythm research.

---

CJC-1295 with DAC vs No DAC

The key difference between versions is duration of activity and hormonal pattern:

Feature	CJC-1295 with DAC	CJC-1295 No DAC
Half-life	~6–8 days	~30 minutes
Release pattern	Sustained GH elevation	Pulsatile GH release
Albumin binding	Yes	No
Research focus	Long-duration GH signaling	Physiological GH pulses

---

Research Applications

CJC-1295 with DAC is studied in preclinical and endocrine research contexts such as:

• Growth hormone axis regulation
• IGF-1 signaling pathway studies
• Pituitary gland responsiveness
• Metabolic rate and energy balance models
• Age-related hormonal decline research
• Protein synthesis and tissue repair signaling

These studies are primarily conducted in laboratory and controlled research environments.

---

Pharmacological Profile (Research Context)

In clinical research literature, CJC-1295 with DAC has been shown to significantly extend GH and IGF-1 elevation compared to native GHRH, due to albumin binding that reduces enzymatic degradation and renal clearance.

This allows researchers to observe long-duration hormonal signaling effects in experimental models.

---

Safety and Regulatory Status

CJC-1295 with DAC is not approved as a medication in most countries, including the United States and the United Kingdom.

Key points:

• Classified as a research-use-only compound in scientific literature
• Human safety profile is not fully established
• Not approved for therapeutic or consumer use
• Limited clinical trial data available

Recent health reporting has also highlighted concerns about unregulated peptide markets and inconsistent product purity in non-laboratory sources.

---

Why Researchers Study CJC-1295 with DAC

Scientific interest in CJC-1295 with DAC continues because it allows researchers to study:

• Long-duration GH signaling
• Hormonal feedback loop suppression or adaptation
• IGF-1 elevation over extended periods
• Endocrine system modulation without daily dosing cycles

This makes it useful for comparative studies against pulsatile GHRH analogs.

---

Conclusion

CJC-1295 with DAC is a long-acting GHRH analog used in scientific research to study growth hormone regulation, metabolic signaling, and endocrine system dynamics. Its unique albumin-binding DAC structure results in sustained hormonal activity, making it distinct from short-acting versions used in pulsatile hormone research.

Ongoing studies continue to explore how prolonged GH elevation influences metabolic and physiological processes in controlled experimental models.